Last reviewed 2026-04-20 · How we verify

Doridamina (LONIDAMINE)

Doridamina works by inhibiting the mitochondrial pyruvate carrier 2, which is involved in the production of energy within cells.

Doridamina, also known as Lonidamine, is a small molecule drug that targets the mitochondrial pyruvate carrier 2. It is classified as a lonidamine drug and has been approved for the treatment of malignant tumors of the lung. The commercial status of Doridamina is currently unknown, and it is not clear if it is patented or available as a generic medication. As a pharmaceutical professional, it is essential to consider the potential safety implications of using this drug, including any unknown side effects or interactions. Further research is needed to fully understand the pharmacokinetics and pharmacodynamics of Doridamina.

At a glance

Mechanism of action

Think of it like a car engine - the mitochondrial pyruvate carrier 2 is like the fuel injector, and Doridamina blocks it from working properly. This can slow down the growth of cancer cells, which need a lot of energy to multiply. By blocking this fuel source, Doridamine can help to slow down the growth of tumors.

Approved indications

• Malignant tumor of lung

Common side effects

No common side effects on file.

Key clinical trials

• Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia (PHASE3)
• Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Doridamina CI brief — competitive landscape report
• Doridamina updates RSS · CI watch RSS